1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

INTRODUCTION

REASONS FOR DOING THE STUDY

This report provides the reader with a detailed analysis of the global sexually transmitted disease (STD) diagnostic and treatment markets. It also discusses technological developments, future trends and emerging opportunities.

The major objectives of this study are:
- To assess the technology developments.
- To identify the driving factors for demand.
- To make available the most current and reliable information on market size.
- To estimate the global supply and demand scenario broken down by disease and geographical regions.
- To estimate the growth rate in demand.
- To estimate the projected global supply and demand scenario over the next five years and to analyze it via application sectors as well as product types.
- To identify the factors influencing this industry and make appropriate recommendations.

Projections for STD diagnostic and treatment applications will be made for geographical regions including the Americas (i.e., U.S., Canada, Central America [including Mexico], South America); Europe, Middle East, Russia and Africa (EMRA); and Asia (Japan, China, India, Australia other Oceanic countries).

SCOPE OF REPORT

This market report organizes information from diverse sources into a cohesive report that includes a disease overview, industry structure, diagnostic products, pharmaceutical products, emerging technology, regulations by region and patents sections.

METHODOLOGY/ INFORMATION SOURCES

The data for this report was gathered from primary and secondary sources. Sources include information obtained from industry analysts; manufacturer and company reports; industry trade journals; medical journals; and industry associations. Additional information was obtained through the U.S. Patent and Trademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, The World Health Organization (WHO), the Organization for Economic Cooperation and Development (OECD), the Pharmaceutical Research and Manufacturing Association, UNAIDS and Epocrates.

When precise information was not available, a projection was made using reasonable assumptions and estimates based on historical data. Market data is based on manufacturers’ sales.

INTENDED AUDIENCE

This updated version of the STD diagnostic and treatment market report will be a valuable tool for decision makers, marketing personnel and manufacturers in both the diagnostic and pharmaceutical treatment industries. Individuals at research foundations, manufacturing companies and university laboratories will find valuable information on the global diagnostic product industries and the pharmaceutical industries.

ANALYST CREDENTIALS

Peggy S. Lehr holds a Bachelor of Science degree in Journalism from the University of Colorado, Boulder, and a Master of Special Studies degree in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor and publisher within the publishing industry for both for-profit and not-for-profit organizations.

REPORT HIGHLIGHTS

This report provides:
- An overview of the markets for the diagnoses of and treatments for sexually transmitted diseases, including bacterial vaginosis, candidiasis, chancroid, chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, HIV/AIDS, pediculosis pubis, syphilis, and trichomoniasis.
- Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Identifications of common STDs, citing risk factors, incidence, and mortality for each.
- Discussion of products on the market.
- A list of current and potential competitors in the market and their market shares.
- Comprehensive company profiles of major players in the industry.

Table Of Contents

Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 1
METHODOLOGY/INFORMATION SOURCES 1
INTENDED AUDIENCE 1
ANALYST CREDENTIALS 2
RELATED BCC REPORTS 2
BCC ONLINE SERVICES 2
DISCLAIMER 2

CHAPTER 2 SUMMARY 4
SUMMARY TABLE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY
TRANSMITTED DISEASES, THROUGH 2017 ($ MILLIONS) 4
SUMMARY FIGURE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY
TRANSMITTED DISEASES, 2011 AND 2017 (%) 4

CHAPTER 3 INDUSTRY OVERVIEW 7
EPIDEMIOLOGY AND ETIOLOGY OF SEXUALLY TRANSMITTED DISEASES 7
TRENDS IN GLOBAL TRANSMISSION OF STDS 7
DIAGNOSIS OF STD 7
VISUAL OBSERVATION 7
BLOOD/TISSUE STAINING 8
AUTOMATED TESTING 8
TABLE 1 MAJOR MANUFACTURERS OF AUTOMATED STD TESTS, 2012 8
NONAUTOMATED STD DIAGNOSTIC TESTING 8
TABLE 2 MAJOR MANUFACTURERS OF RAPID AND LABORATORY DIAGNOSTIC STD KITS,
2012 8
VACCINES 9
TABLE 3 MAJOR MANUFACTURERS OF VACCINES FOR STDS 9
MARKET ANALYSIS BY DISEASE 9
HPV/GENITAL WARTS 10
Diagnostic Product Market 10
TABLE 4 HPV DIAGNOSTIC PRODUCTS, MANUFACTURER AND MARKET SHARE, 2011 (%) 10
GONORRHEA 10
Diagnostic Product Market 10
TABLE 5 GONORRHEA DIAGNOSTIC PRODUCT MANUFACTURERS AND PRODUCT NAMES 11
Treatment Market 11
TABLE 6 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS 11
HEPATITIS A, B AND C 12
Diagnostic Product Market 12
TABLE 7 HEPATITIS A, B AND C DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY
TYPE OF TEST, 2011 ($ MILLIONS/%) 12
Treatment Market 12
TABLE 8 MARKET STANDING OF MAJOR HEPATITIS B AND C TREATMENT
MANUFACTURERS BY REVENUES, 2011 ($ MILLIONS) 13
FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND
THEIR MARKET SHARE, 2011 (%) 13
HIV/AIDS 14
Diagnostic Market 14
TABLE 9 HIV DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE, 2011 ($
MILLIONS/%) 14
Treatment Market 14
TABLE 10 HIV/AIDS TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2011
($ MILLIONS/%) 15
FIGURE 2 MARKET SHARE OF LEADING COMPANIES IN THE HIV/AIDS TREATMENT
MARKET, 2011 (%) 15
MARKET SHARE, BY DISEASE 16
TABLE 11 NUMBER OF DIAGNOSTIC AND PHARMACEUTICAL MANUFACTURERS, BY
DISEASE TREATED, WITH REVENUES AND MARKET SHARE, 2011 ($ MILLIONS/%) 16
MERGERS AND ACQUISITIONS 16
TABLE 12 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 ($ MILLIONS) 16

CHAPTER 4 DISEASE OVERVIEW 19
TABLE 13 CAUSATIVE ORGANISMS FOR SEXUALLY TRANSMITTED DISEASES 19
DIAGNOSTIC TESTING 19
FLUORESCENT IMMUNOASSAY (FIA) 20
Direct Fluorescent Antibody Testing 20
Indirect Fluorescent Antibody Testing 20
Chemiluminescent Microparticle Immunoassay 20
ENZYME IMMUNOASSAY 20
Basic EIA 21
Enzyme-linked Immunosorbent Assay (ELISA) 21
GENE PROBE ANALYSIS 21
Polymerase Chain Reaction Amplification 22
Nucleic Acid Amplification Test (NAT) 22
Transcription-Mediated Amplification (TMA) 22
Nucleic Acid Sequence-Based Amplification (NASBA) 22
Dual Kinetic Assay (DKA) 23
BACTERIAL VAGINOSIS 23
OVERVIEW 23
RISK FACTORS 23
INCIDENCE 24
DIAGNOSTIC PROCEDURES 24
TABLE 14 CURRENT DIAGNOSTIC TESTS FOR BACTERIAL VAGINITIS 24
TREATMENTS 24
TABLE 15 CURRENT TREATMENTS FOR BACTERIAL VAGINITIS 25
CANDIDIASIS 25
OVERVIEW 25
RISK FACTORS 25
INCIDENCE 25
DIAGNOSTIC PROCEDURES 25
TABLE 16 DIAGNOSTIC TESTS FOR CANDIDIASIS 25
TREATMENT 26
TABLE 17 TREATMENTS FOR VULVOVAGINAL CANDIDIASIS 26
CHANCROID (VENEREAL ULCERS) 27
OVERVIEW 27
RISK FACTORS 27
INCIDENCE 27
DIAGNOSTIC PROCEDURES 28
TREATMENTS 28
TABLE 18 CURRENT MEDICATIONS USED TO TREAT CHANCROID ULCERS 28
CHLAMYDIA 28
OVERVIEW 28
RISK FACTORS 29
INCIDENCE 29
DIAGNOSTIC PROCEDURES 30
TABLE 19 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND
MANUFACTURER, 2012 30
TREATMENTS 31
TABLE 20 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA 31
GENITAL HERPES 32
OVERVIEW 32
RISK FACTORS 32
INCIDENCE 32
DIAGNOSTIC PROCEDURES 32
TABLE 21 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPESBY
BRAND NAME, TYPE AND MANUFACTURER, 2012 32
TREATMENTS 33
TABLE 22 CURRENT TREATMENTS FOR GENITAL HERPESBY BRAND NAME, GENERIC NAME
AND MANUFACTURER, 2012 34
GENITAL WARTS/HUMAN PAPILLOMAVIRUS 34
OVERVIEW 34
RISK FACTORS 34
INCIDENCE 35
DIAGNOSTIC PROCEDURES 35
TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME,
TYPE AND MANUFACTURER, 2012 35
TREATMENTS 35
TABLE 24 MEDICATIONS USED TO TREAT GENITAL WARTS BY BRAND NAME, GENERIC
NAME AND MANUFACTURER 36
GONORRHEA 36
OVERVIEW 36
RISK FACTORS 36
Age 15 to 24 Years 36
Black Heritage 37
Additional Risk Factors 37
INCIDENCE 37
DIAGNOSTIC PROCEDURES 37
TABLE 25 CURRENT PRODUCTS USED TO DIAGNOSE GONORRHEA 37
TREATMENTS 38
TABLE 26 CURRENT MEDICATIONS USED TO TREAT GONORRHEA 38
HEPATITIS B AND C 39
OVERVIEW 39
RISK FACTORS 39
INCIDENCE 39
DIAGNOSTIC PROCEDURES 40
TABLE 27 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY
BRAND NAME, TYPE AND MANUFACTURER, 2012 40
TREATMENTS 41
TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012 42
HERPES SIMPLEX VIRUS (SEE GENITAL HERPES) 43
HIV/AIDS 43
OVERVIEW 43
TABLE 29 CDC CLASSIFICATION OF HIV INFECTION 43
RISK FACTORS 44
Condoms and Preventing HIV 44
INCIDENCE/MORTALITY 44
DIAGNOSTIC PROCEDURES 45
TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS BY BRAND
NAME, TYPE AND MANUFACTURER, 2012 45
TREATMENTS 46
TABLE 31 HIV LIFE CYCLE 46
Generic Treatments 46
TABLE 32 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2012 47
Brand Name HIV Treatments 48
TABLE 33 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF
HIV/AIDS BY BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012 48
BRANDED TREATMENT MARKET, BY MAJOR MANUFACTURER 49
TABLE 34 HIV TREATMENT MARKET, BY MANUFACTURER ($ MILLIONS) 49
FIGURE 3 2011 MARKET SHARE FOR BRANDED HIV DRUGS, BY MANUFACTURER (%) 50
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) 50
HAART Failure 51
Mega HAART 51
PEDIATRIC HIV 51
Smaller Pediatric Market 51
Complicated Treatment Regimen 52
PEDICULOSIS PUBIS 52
OVERVIEW 52
RISK FACTORS 52
INCIDENCE 52
DIAGNOSTIC PROCEDURES 52
TREATMENTS 53
TABLE 35 CURRENT TREATMENTS FOR PEDICULOSIS PUBIS BRAND NAME, GENERIC
NAME AND MANUFACTURER 53
PELVIC INFLAMMATORY DISEASE (PID) 53
OVERVIEW 53
RISK FACTORS 53
INCIDENCE 54
DIAGNOSIS 54
TREATMENT 54
TABLE 36 CURRENT TREATMENTS FOR PID BRAND NAME, GENERIC NAME AND
MANUFACTURER 54
SCABIES 55
OVERVIEW 55
RISK FACTORS 55
INCIDENCE 55
DIAGNOSTIC PROCEDURES 56
TREATMENTS 56
TABLE 37 CURRENT TREATMENTS FOR SCABIES BRAND NAME, GENERIC NAME AND
MANUFACTURER 56
SYPHILIS 56
OVERVIEW 56
TABLE 38 STAGES OF SYPHILIS 57
RISK FACTORS 57
INCIDENCE 57
U.S. 58
Western Europe, Russia 58
DIAGNOSTIC PROCEDURES 58
TABLE 39 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND
NAME, TYPE AND MANUFACTURER, 2012 58
TREATMENTS 59
TRICHOMONIASIS 59
OVERVIEW 59
RISK FACTORS 60
INCIDENCE 60
DIAGNOSTIC PROCEDURES 60
TABLE 40 DIAGNOSTIC ASSAYS FOR DETECTION OF TRICHOMONAS WITH BRAND NAME,
TYPE AND MANUFACTURER 60
TREATMENTS 60
TABLE 41 CURRENT MEDICATIONS FOR THE TREATMENT OF TRICHOMONAS 61
STD TRENDS 61
GLOBAL CONDOM USE 61
U.S. 61
Gonorrhea 61
Chlamydia 61
Syphilis 61
HIV/AIDs 62
EMRA 62
Gonorrhea 62
Chlamydia 62
Hepatitis B 62
Hepatitis C 63
HIV/AIDS 63
Syphilis 63
ASIA 64
Gonorrhea 64
Chlamydia 64
HIV/AIDS 64
Hepatitis 64

CHAPTER 5 STD DIAGNOSIS AND TREATMENT OPTIONS 66
DIAGNOSTIC OPTIONS, BY TYPE 66
FIGURE 4 MARKET SHARE FOR TYPES OF TESTS USED TO DIAGNOSE STDS, 2012 (%) 66
GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS, BY DISEASE 67
TABLE 42 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT
STDS BY DISEASE, THROUGH 2017 ($ MILLIONS) 67
PROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS, BY REGION 68
TABLE 43 PROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS BY REGION,
THROUGH 2017 ($ MILLIONS) 68
FIGURE 5 GLOBAL STD DIAGNOSTIC MARKET, BY REGION 2012 AND 2017 (%) 69
STD PHARMACEUTICAL PRODUCTS, BY DISEASE 69
TABLE 44 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS, THROUGH
2017 ($ MILLIONS) 70
GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS, BY REGION 70
TABLE 45 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS BY
REGION, THROUGH 2017 ($ MILLIONS) 70
FIGURE 6 GLOBAL STD PHARMACEUTICAL MARKET BY REGION 2012 AND 2017 (%) 71
OPPORTUNITIES IN THE STD DIAGNOSIS AND TREATMENT MARKET 71
OPPORTUNITIES IN THE HIV/AIDS MARKET 72
Diagnostics 72
Pharmaceuticals 73
Immediate term 73
Medium-term priorities 73
OPPORTUNITIES IN THE HEPATITIS MARKET 74
Pharmaceutical Opportunities in the Hepatitis Market 74
OTHER STDS 74
Diagnostic Testing 74

CHAPTER 6 THE AMERICAS MARKET 76
DIAGNOSTIC PRODUCTS IN THE AMERICAS 76
MARKET FOR DIAGNOSTIC PRODUCTS IN THE AMERICAS 76
TABLE 46 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS,
THROUGH 2017 ($ MILLIONS) 76
FIGURE 7 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS BY DISEASE, 2012
AND 2017 (%) 76
PHARMACEUTICAL TREATMENTS IN THE AMERICAS 78
TABLE 47 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS,
BY DISEASE, THROUGH 2017 ($ MILLIONS) 78
FIGURE 8 MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS BY DISEASE,
2012 AND 2017 (%) 79
ANTIBIOTIC RESISTANCE IN TREATING STDS 79
THE U.S. 80
STD AND PREGNANCY 80
Problems for the Child at Birth 80
Treatments for STDs During Pregnancy 80
TABLE 48 ESTIMATED ANNUAL NUMBER OF PREGNANT WOMEN WITH AN STD IN THE U.S. 80
ANNUAL INCIDENCE OF STDS IN THE U.S. 81
TABLE 49 ANNUAL INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., 2010
(PER 100,000 PEOPLE) 81
Gonorrhea 81
Chlamydia 82
Syphilis 82
HIV 82
HIV and Women 82
Hepatitis B 82
Hepatitis C 82
LATIN/SOUTH AMERICA 83
HIV 83
HIV Treatment in Central/South America 83
CANADA 83
HIV IN CANADA 83
HEPATITIS IN CANADA 84
CHLAMYDIA IN CANADA 84
SYPHILIS IN CANADA 84
GONORRHEA IN CANADA 84

CHAPTER 7 THE EMRA MARKET 86
STD DIAGNOSTIC PRODUCT MARKET IN THE EMRA 86
TABLE 50 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA, THROUGH
2017 ($ MILLIONS) 86
FIGURE 9 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA BY DISEASE, 2012 AND
2017 (%) 86
STD PHARMACEUTICAL TREATMENTS IN THE EMRA 87
TABLE 51 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE EMRA BY
DISEASE, THROUGH 2017 ($ MILLIONS) 87
FIGURE 10 MARKET FOR STD TREATMENT PRODUCTS IN THE EMRA BY DISEASE, 2012 AND
2017 (%) 88
ANNUAL INCIDENCES OF STD DISEASE IN THE EMRA 89
UNITED KINGDOM 89
Chlamydia 89
HSV 89
HPV 89
Syphilis 90
HIV IN EUROPE 90
HEPATITIS B, C IN EUROPE 90
Hepatitis C 90
CHLAMYDIA AND GONORRHEA IN EUROPE 90
Gonorrhea 91
SYPHILIS IN EUROPE 91
HIV IN AFRICA 91
Access to Therapeutics in Africa 92
Hepatitis in Africa 92
RUSSIA, EASTERN EUROPE, CENTRAL ASIA 92
HIV 92
HIV Treatments in the Region 92
Hepatitis 92
MIDDLE EAST 93
HIV 93

CHAPTER 8 THE ASIAN MARKET 95
DIAGNOSTIC PRODUCTS 95
TABLE 52 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE,
THROUGH 2017 ($ MILLIONS) 95
FIGURE 11 MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017
(%) 95
STD TREATMENT OPTIONS IN ASIA 96
TABLE 53 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN ASIA BY
DISEASE, THROUGH 2017 ($ MILLIONS) 97
FIGURE 12 MARKET FOR STD TREATMENT PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017
(%) 97
REGIONAL DISEASE PREVALENCE 98
CHINA 99
HIV 99
HIV Testing and Treatment 99
INDIA 99
HIV 99
Testing 100
Treatment 100
Hepatitis in India 100
AUSTRALIA 100
JAPAN 100
HIV 100
Hepatitis 101

CHAPTER 9 REGULATIONS 103
CREATING DRUG TREATMENTS 103
TABLE 54 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 103
REGIONAL REGULATIONS 104
THE AMERICAS 104
Surveys 104
Canada 104
EMRA 105
Diagnostic Products in EU 105
ASIA 105
Japan 105
Diagnostic Regulations 105
Pharmaceutical Regulations 106
China 106
India 106

CHAPTER 10 PHARMACEUTICAL TREATMENT PIPELINE 108
EMERGING TRENDS IN DIAGNOSTIC PRODUCTS 108
MICROFLUIDIC PAPER-BASED PRODUCTS 108
Microfluidic Detection and Telemedicine 108
EMERGING TRENDS IN PHARMACEUTICAL PRODUCTS 109
CHLAMYDIA 109
HERPES SIMPLEX VIRUS 109
Astellas Helicase Inhibitors 109
HIV/AIDS 109
Merck 110
Gilead Sciences 110
GlaxoSmithKline 110
HEPATITIS 111
Gilead Sciences 111
Janssen Pharmaceuticals/Tibotech Pharmaceuticals 111
Merck 111
Roche 111
Boehringer Ingelheim 112
Vertex Pharmaceuticals 112
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE 112
TABLE 55 SEXUALLY TRANSMITTED DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012 113

CHAPTER 11 PATENT ANALYSIS 118
PHARMACEUTICAL PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE 118
TABLE 56 STD PHARMACEUTICAL PATENTS BY PATENT NUMBER, DISEASE, COMPANY,
PRODUCT DESCRIPTION, AND APPROVAL DATE FEBRUARY 2006-OCTOBER 2012 119
DIAGNOSTIC PATENTS ISSUED BY COMPANY, APPROVAL DATE AND DISEASE 122
TABLE 57 STD DIAGNOSTIC PATENTS BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT
DESCRIPTION AND APPROVAL DATE MARCH 2005-OCTOBER 2012 123
PATENTS ISSUED BY COMPANY 124
TABLE 58 STD PHARMACEUTICAL PRODUCT PATENTS, BY MAJOR COMPANY JANUARY
2005-OCTOBER 2012 124
PATENTS ISSUED BY COUNTRY 125
TABLE 59 STD DIAGNOSIS AND TREATMENT PATENTS BY COUNTRY JANUARY
2005-OCTOBER 2012 125
PATENTS ISSUED BY DISEASE 126
TABLE 60 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF STDS BY DISEASE,
MARCH 2005-OCTOBER 2012 126

CHAPTER 12 COMPANY PROFILES 128
ABBOTT LABORATORIES 128
TABLE 61 ABBOTT PHARMACEUTICAL PRODUCTS 128
TABLE 62 ABBOTT DIAGNOSTIC PRODUCTS 128
ALERE 129
TABLE 63 ALERE DIAGNOSTIC PRODUCTS 129
ALFA SCIENTIFIC DESIGNS 130
TABLE 64 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS 130
ATLAS LINK BIOTECH CO, LTD. 130
TABLE 65 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS 131
BAYER AG 131
TABLE 66 BAYER PHARMACEUTICAL PRODUCTS 131
BECTON DICKINSON 131
TABLE 67 BECTON DICKINSON DIAGNOSTIC PRODUCTS 132
BIOMERIEUX, INC. 132
TABLE 68 BIOMERIEUX DIAGNOSTIC PRODUCTS 132
BIO-RAD LABORATORIES 132
TABLE 69 BIO-RAD LABORATORIES DIAGNOSTIC PRODUCTS 133
BOEHRINGER INGELHEIM GMBH 133
TABLE 70 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS 133
BRISTOL-MYERS SQUIBB COMPANY 134
TABLE 71 BRISTOL-MEYERS SQUIBB PHARMACEUTICAL PRODUCTS 134
CREATIVE DIAGNOSTICS 134
TABLE 72 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS 135
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS, INC. 135
TABLE 73 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS 135
DIASORIN 136
TABLE 74 DIASORIN DIAGNOSTIC PRODUCTS 136
ENZO BIOCHEM 136
TABLE 75 ENZO BIOCHEM DIAGNOSTIC PRODUCTS 137
FIRST DIAGNOSTIC LLC 137
TABLE 76 FIRST DIAGNOSTIC DIAGNOSTIC PRODUCTS 137
GENENTECH (SEE ROCHE) 138
GEN-PROBE, INC. (SEE HOLOGIC) 138
GILEAD SCIENCES, INC. 138
TABLE 77 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS 138
GLAXOSMITHKLINE 138
TABLE 78 GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS 139
HOLOGIC/GEN-PROBE 139
TABLE 79 HOLOGIC/GEN-PROBE DIAGNOSTIC PRODUCTS 139
HOME ACCESS HEALTH, INC. 140
TABLE 80 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS 140
IMMUNOSTICS 140
TABLE 81 IMMUNOSTICS DIAGNOSTIC PRODUCTS 140
IND DIAGNOSTIC, INC. 141
TABLE 82 IND DIAGNOSTIC, INC DIAGNOSTIC PRODUCTS 141
INVERNESS MEDICAL INNOVATIONS (SEE ALERE) 141
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS) 141
TABLE 83 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS 142
MERCK and COMPANY, INC. 142
TABLE 84 MERCK PHARMACEUTICAL PRODUCTS 142
MERIDIAN BIOSCIENCE 143
TABLE 85 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS 143
NOVARTIS PHARMACEUTICAL CORPORATION 143
TABLE 86 NOVARTIS DIAGNOSTIC PRODUCTS 144
ORASURE TECHNOLOGIES, INC. 144
TABLE 87 ORASURE TECHNOLOGIES DIAGNOSTIC PRODUCTS 144
ORTHO CLINICAL DIAGNOSTICS 144
TABLE 88 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS 145
PFIZER, INC. 145
TABLE 89 PFIZER PHARMACEUTICAL PRODUCTS 145
PRINCETON BIOMEDITECH CORPORATION 146
TABLE 90 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS 146
QIAGEN BENELUX BV 146
TABLE 91 QIAGEN DIAGNOSTIC PRODUCTS 146
QUIDEL 147
TABLE 92 QUIDEL DIAGNOSTIC PRODUCTS 147
REMEL/THERMOFISHER SCIENTIFIC 147
TABLE 93 REMEL/THERMOFISHER SCIENTIFIC DIAGNOSTIC PRODUCTS 148
ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.) 148
TABLE 94 ROCHE PHARMACEUTICAL PRODUCTS 148
TABLE 95 ROCHE DIAGNOSTIC PRODUCTS 148
SEKISUI DIAGNOSTICS 149
TABLE 96 SEKISUI DIAGNOSTICS DIAGNOSTIC PRODUCTS 149
SHANGHAI KEHUA BIO-ENGINEERING CO, LTD. 149
TABLE 97 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS 149
STANDARD DIAGNOSTICS, INC. 150
TABLE 98 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS 150
TRINITY BIOTECH PLC 151
TABLE 99 TRINITY BIOTECH DIAGNOSTIC PRODUCTS 151
VERTEX PHARMACEUTICALS 152
TABLE 100 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS 152
VIIV HEALTHCARE 152
TABLE 101 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS 152



LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY
TRANSMITTED DISEASES, THROUGH 2017 ($ MILLIONS) 4
TABLE 1 MAJOR MANUFACTURERS OF AUTOMATED STD TESTS, 2012 8
TABLE 2 MAJOR MANUFACTURERS OF RAPID AND LABORATORY DIAGNOSTIC STD KITS, 2012 8
TABLE 3 MAJOR MANUFACTURERS OF VACCINES FOR STDS 9
TABLE 4 HPV DIAGNOSTIC PRODUCTS, MANUFACTURER AND MARKET SHARE, 2011 (%) 10
TABLE 5 GONORRHEA DIAGNOSTIC PRODUCT MANUFACTURERS AND PRODUCT NAMES 11
TABLE 6 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS 11
TABLE 7 HEPATITIS A, B AND C DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY
TYPE OF TEST, 2011 ($ MILLIONS/%) 12
TABLE 8 MARKET STANDING OF MAJOR HEPATITIS B AND C TREATMENT MANUFACTURERS
BY REVENUES, 2011 ($ MILLIONS) 13
TABLE 9 HIV DIAGNOSTIC PRODUCT MARKET SHARE AND REVENUES BY TYPE, 2011 ($
MILLIONS/%) 14
TABLE 10 HIV/AIDS TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2011
($ MILLIONS/%) 15
TABLE 11 NUMBER OF DIAGNOSTIC AND PHARMACEUTICAL MANUFACTURERS, BY DISEASE
TREATED, WITH REVENUES AND MARKET SHARE, 2011 ($ MILLIONS/%) 16
TABLE 12 SELECTED MERGERS AND ACQUISITIONS, 2008-2012 ($ MILLIONS) 16
TABLE 13 CAUSATIVE ORGANISMS FOR SEXUALLY TRANSMITTED DISEASES 19
TABLE 14 CURRENT DIAGNOSTIC TESTS FOR BACTERIAL VAGINITIS 24
TABLE 15 CURRENT TREATMENTS FOR BACTERIAL VAGINITIS 25
TABLE 16 DIAGNOSTIC TESTS FOR CANDIDIASIS 25
TABLE 17 TREATMENTS FOR VULVOVAGINAL CANDIDIASIS 26
TABLE 18 CURRENT MEDICATIONS USED TO TREAT CHANCROID ULCERS 28
TABLE 19 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND
MANUFACTURER, 2012 30
TABLE 20 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA 31
TABLE 21 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPESBY
BRAND NAME, TYPE AND MANUFACTURER, 2012 32
TABLE 22 CURRENT TREATMENTS FOR GENITAL HERPESBY BRAND NAME, GENERIC NAME
AND MANUFACTURER, 2012 34
TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME,
TYPE AND MANUFACTURER, 2012 35
TABLE 24 MEDICATIONS USED TO TREAT GENITAL WARTS BY BRAND NAME, GENERIC
NAME AND MANUFACTURER 36
TABLE 25 CURRENT PRODUCTS USED TO DIAGNOSE GONORRHEA 37
TABLE 26 CURRENT MEDICATIONS USED TO TREAT GONORRHEA 38
TABLE 27 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY
BRAND NAME, TYPE AND MANUFACTURER, 2012 40
TABLE 28 VACCINES AND MEDICATIONS FOR THE TREATMENT OF HEPATITIS, 2012 42
TABLE 29 CDC CLASSIFICATION OF HIV INFECTION 43
TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HIV/AIDS BY BRAND NAME, TYPE AND MANUFACTURER, 2012 45
TABLE 31 HIV LIFE CYCLE 46
TABLE 32 FDA-APPROVED GENERIC DRUGS FOR TREATMENT OF HIV, 2012 47
TABLE 33 CURRENTLY APPROVED PHARMACEUTICAL PRODUCTS FOR TREATMENT OF
HIV/AIDS BY BRAND NAME, GENERIC NAME AND MANUFACTURER, 2012 48
TABLE 34 HIV TREATMENT MARKET, BY MANUFACTURER ($ MILLIONS) 49
TABLE 35 CURRENT TREATMENTS FOR PEDICULOSIS PUBIS BRAND NAME, GENERIC NAME
AND MANUFACTURER 53
TABLE 36 CURRENT TREATMENTS FOR PID BRAND NAME, GENERIC NAME AND
MANUFACTURER 54
TABLE 37 CURRENT TREATMENTS FOR SCABIES BRAND NAME, GENERIC NAME AND
MANUFACTURER 56
TABLE 38 STAGES OF SYPHILIS 57
TABLE 39 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012 58
TABLE 40 DIAGNOSTIC ASSAYS FOR DETECTION OF TRICHOMONAS WITH BRAND NAME,
TYPE AND MANUFACTURER 60
TABLE 41 CURRENT MEDICATIONS FOR THE TREATMENT OF TRICHOMONAS 61
TABLE 42 PROJECTED GLOBAL MARKET FOR DIAGNOSTIC PRODUCTS USED TO DETECT
STDS BY DISEASE, THROUGH 2017 ($ MILLIONS) 67
TABLE 43 PROJECTED GLOBAL MARKET FOR STD DIAGNOSTIC PRODUCTS BY REGION,
THROUGH 2017 ($ MILLIONS) 68
TABLE 44 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS, THROUGH
2017 ($ MILLIONS) 70
TABLE 45 PROJECTED GLOBAL MARKET FOR STD PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 70
TABLE 46 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS,
THROUGH 2017 ($ MILLIONS) 76
TABLE 47 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS,
BY DISEASE, THROUGH 2017 ($ MILLIONS) 78
TABLE 48 ESTIMATED ANNUAL NUMBER OF PREGNANT WOMEN WITH AN STD IN THE U.S. 80
TABLE 49 ANNUAL INCIDENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., 2010
(PER 100,000 PEOPLE) 81
TABLE 50 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA, THROUGH
2017 ($ MILLIONS) 86
TABLE 51 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE EMRA BY
DISEASE, THROUGH 2017 ($ MILLIONS) 87
TABLE 52 PROJECTED MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE,
THROUGH 2017 ($ MILLIONS) 95
TABLE 53 PROJECTED MARKET FOR STD PHARMACEUTICAL PRODUCTS IN ASIA BY DISEASE,
THROUGH 2017 ($ MILLIONS) 97
TABLE 54 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 103
TABLE 55 SEXUALLY TRANSMITTED DISEASE PHARMACEUTICAL PRODUCT PIPELINE, 2012 113
TABLE 56 STD PHARMACEUTICAL PATENTS BY PATENT NUMBER, DISEASE, COMPANY,
PRODUCT DESCRIPTION, AND APPROVAL DATE FEBRUARY 2006-OCTOBER 2012 119
TABLE 57 STD DIAGNOSTIC PATENTS BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT
DESCRIPTION AND APPROVAL DATE MARCH 2005-OCTOBER 2012 123
TABLE 58 STD PHARMACEUTICAL PRODUCT PATENTS, BY MAJOR COMPANY JANUARY
2005-OCTOBER 2012 124
TABLE 59 STD DIAGNOSIS AND TREATMENT PATENTS BY COUNTRY JANUARY 2005-OCTOBER 2012 125
TABLE 60 PATENTS ISSUED FOR DIAGNOSIS AND TREATMENT OF STDS BY DISEASE, MARCH 2005-OCTOBER 2012 126
TABLE 61 ABBOTT PHARMACEUTICAL PRODUCTS 128
TABLE 62 ABBOTT DIAGNOSTIC PRODUCTS 128
TABLE 63 ALERE DIAGNOSTIC PRODUCTS 129
TABLE 64 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS 130
TABLE 65 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS 131
TABLE 66 BAYER PHARMACEUTICAL PRODUCTS 131
TABLE 67 BECTON DICKINSON DIAGNOSTIC PRODUCTS 132
TABLE 68 BIOMERIEUX DIAGNOSTIC PRODUCTS 132
TABLE 69 BIO-RAD LABORATORIES DIAGNOSTIC PRODUCTS 133
TABLE 70 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS 133
TABLE 71 BRISTOL-MEYERS SQUIBB PHARMACEUTICAL PRODUCTS 134
TABLE 72 CREATIVE DIAGNOSTICS DIAGNOSTIC PRODUCTS 135
TABLE 73 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS 135
TABLE 74 DIASORIN DIAGNOSTIC PRODUCTS 136
TABLE 75 ENZO BIOCHEM DIAGNOSTIC PRODUCTS 137
TABLE 76 FIRST DIAGNOSTIC DIAGNOSTIC PRODUCTS 137
TABLE 77 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS 138
TABLE 78 GLAXOSMITHKLINE PHARMACEUTICAL PRODUCTS 139
TABLE 79 HOLOGIC/GEN-PROBE DIAGNOSTIC PRODUCTS 139
TABLE 80 HOME ACCESS HEALTH DIAGNOSTIC PRODUCTS 140
TABLE 81 IMMUNOSTICS DIAGNOSTIC PRODUCTS 140
TABLE 82 IND DIAGNOSTIC, INC DIAGNOSTIC PRODUCTS 141
TABLE 83 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS 142
TABLE 84 MERCK PHARMACEUTICAL PRODUCTS 142
TABLE 85 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS 143
TABLE 86 NOVARTIS DIAGNOSTIC PRODUCTS 144
TABLE 87 ORASURE TECHNOLOGIES DIAGNOSTIC PRODUCTS 144
TABLE 88 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS 145
TABLE 89 PFIZER PHARMACEUTICAL PRODUCTS 145
TABLE 90 PRINCETON BIOMEDITECH DIAGNOSTIC PRODUCTS 146
TABLE 91 QIAGEN DIAGNOSTIC PRODUCTS 146
TABLE 92 QUIDEL DIAGNOSTIC PRODUCTS 147
TABLE 93 REMEL/THERMOFISHER SCIENTIFIC DIAGNOSTIC PRODUCTS 148
TABLE 94 ROCHE PHARMACEUTICAL PRODUCTS 148
TABLE 95 ROCHE DIAGNOSTIC PRODUCTS 148
TABLE 96 SEKISUI DIAGNOSTICS DIAGNOSTIC PRODUCTS 149
TABLE 97 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS 149
TABLE 98 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS 150
TABLE 99 TRINITY BIOTECH DIAGNOSTIC PRODUCTS 151
TABLE 100 VERTEX PHARMACEUTICALS PHARMACEUTICAL PRODUCTS 152
TABLE 101 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS 152



LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR TREATMENT AND DIAGNOSIS OF SEXUALLY
TRANSMITTED DISEASES, 2011 AND 2017 (%) 4
FIGURE 1 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR
MARKET SHARE, 2011 (%) 13
FIGURE 2 MARKET SHARE OF LEADING COMPANIES IN THE HIV/AIDS TREATMENT MARKET,
2011 (%) 15
FIGURE 3 2011 MARKET SHARE FOR BRANDED HIV DRUGS, BY MANUFACTURER (%) 50
FIGURE 4 MARKET SHARE FOR TYPES OF TESTS USED TO DIAGNOSE STDS, 2012 (%) 66
FIGURE 5 GLOBAL STD DIAGNOSTIC MARKET, BY REGION 2012 AND 2017 (%) 69
FIGURE 6 GLOBAL STD PHARMACEUTICAL MARKET BY REGION 2012 AND 2017 (%) 71
FIGURE 7 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE AMERICAS BY DISEASE, 2012
AND 2017 (%) 76
FIGURE 8 MARKET FOR STD PHARMACEUTICAL PRODUCTS IN THE AMERICAS BY DISEASE,
2012 AND 2017 (%) 79
FIGURE 9 MARKET FOR STD DIAGNOSTIC PRODUCTS IN THE EMRA BY DISEASE, 2012 AND
2017 (%) 86
FIGURE 10 MARKET FOR STD TREATMENT PRODUCTS IN THE EMRA BY DISEASE, 2012 AND
2017 (%) 88
FIGURE 11 MARKET FOR STD DIAGNOSTIC PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017
(%) 95
FIGURE 12 MARKET FOR STD TREATMENT PRODUCTS IN ASIA BY DISEASE, 2012 AND 2017
(%) 97

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Sexually-Transmitted Diseases (STDs): Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis

Sexually-Transmitted Diseases (STDs): Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis

  • $ 6200
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $9,600.  DataPack (test volumes, sales forecasts, supplier shares) $6,200. This new 350-page report from VPGMarketResearch.com contains 90 tables and provides analysis of the global s ...

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) ...

Europe Sexually-Transmitted Diseases (STDs): Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis

Europe Sexually-Transmitted Diseases (STDs): Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, Syphilis

  • $ 5100
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $7,900.  DataPack (test volumes, sales forecasts, supplier shares) $5,100. This new 318-page report from VPGMarketResearch.com provides analysis of the European sexually-transmitted disease ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.